These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Guest editors' note: special issue on recent developments in statistical approaches for chemistry and manufacturing control (CMC) and quality-by-design(QbD). Tsong Y; Yang H J Biopharm Stat; 2015; 25(2):233. PubMed ID: 25437635 [No Abstract] [Full Text] [Related]
7. An Intercompany Perspective on Biopharmaceutical Drug Product Robustness Studies. Morar-Mitrica S; Adams ML; Crotts G; Wurth C; Ihnat PM; Tabish T; Antochshuk V; DiLuzio W; Dix DB; Fernandez JE; Gupta K; Fleming MS; He B; Kranz JK; Liu D; Narasimhan C; Routhier E; Taylor KD; Truong N; Stokes ESE J Pharm Sci; 2018 Feb; 107(2):529-542. PubMed ID: 29074375 [TBL] [Abstract][Full Text] [Related]
8. The central role of chemistry in 'quality by design' approaches to drug development. Grewal NK; Leadbeater NE Future Med Chem; 2012 Sep; 4(14):1799-810. PubMed ID: 23043477 [TBL] [Abstract][Full Text] [Related]
9. A practical discussion of risk management for manufacturing of pharmaceutical products. Mollah AH; Baseman HS; Long M; Rathore AS PDA J Pharm Sci Technol; 2014; 68(3):271-80. PubMed ID: 25188348 [TBL] [Abstract][Full Text] [Related]
15. Characterization and establishment of specifications for biopharmaceuticals. Davis GC; Riggin RM Dev Biol Stand; 1997; 91():49-54. PubMed ID: 9413683 [TBL] [Abstract][Full Text] [Related]
16. A quality by design study applied to an industrial pharmaceutical fluid bed granulation. Lourenço V; Lochmann D; Reich G; Menezes JC; Herdling T; Schewitz J Eur J Pharm Biopharm; 2012 Jun; 81(2):438-47. PubMed ID: 22446063 [TBL] [Abstract][Full Text] [Related]
17. PDA workshop on "Quality by Design for Biopharmaceuticals: Concepts and Implementation", May 21-22, 2007, Bethesda, Maryland. Rathore AS; Devine R PDA J Pharm Sci Technol; 2008; 62(5):380-90. PubMed ID: 19055233 [TBL] [Abstract][Full Text] [Related]
18. Scientific and Regulatory Considerations in Solid Oral Modified Release Drug Product Development. Li M; Sander S; Duan J; Rosencrance S; Miksinski SP; Yu L; Seo P; Rege B AAPS J; 2016 Nov; 18(6):1406-1417. PubMed ID: 27650190 [TBL] [Abstract][Full Text] [Related]
19. Quality by design approach for formulation development: a case study of dispersible tablets. Charoo NA; Shamsher AA; Zidan AS; Rahman Z Int J Pharm; 2012 Feb; 423(2):167-78. PubMed ID: 22209997 [TBL] [Abstract][Full Text] [Related]
20. A Quality by Design Approach to Developing and Manufacturing Polymeric Nanoparticle Drug Products. Troiano G; Nolan J; Parsons D; Van Geen Hoven C; Zale S AAPS J; 2016 Nov; 18(6):1354-1365. PubMed ID: 27631558 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]